EA201301266A1 - PHARMACEUTICAL COMPOSITION CONTAINING NALBUFIN HYDROCHLORIDE, ITS APPLICATION FOR THE TREATMENT OF MEDICAL SYNDROME OF MEDIUM AND HIGH INTENSITY AND METHOD OF OBTAINING THE PHARMACEUTICAL COMPOSITION - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING NALBUFIN HYDROCHLORIDE, ITS APPLICATION FOR THE TREATMENT OF MEDICAL SYNDROME OF MEDIUM AND HIGH INTENSITY AND METHOD OF OBTAINING THE PHARMACEUTICAL COMPOSITION

Info

Publication number
EA201301266A1
EA201301266A1 EA201301266A EA201301266A EA201301266A1 EA 201301266 A1 EA201301266 A1 EA 201301266A1 EA 201301266 A EA201301266 A EA 201301266A EA 201301266 A EA201301266 A EA 201301266A EA 201301266 A1 EA201301266 A1 EA 201301266A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
high intensity
pharmaceutical composition
moderate
poloxamer
Prior art date
Application number
EA201301266A
Other languages
Russian (ru)
Other versions
EA201301266A8 (en
EA023024B1 (en
Inventor
Николай Александрович ЛЯПУНОВ
Игорь Альбертович ЗУПАНЕЦ
Юрий Михайлович СТОЛПЕР
Сергей Константинович ШЕБЕКО
Original Assignee
Общество с ограниченной ответственностью "НПК "Трифарма"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "НПК "Трифарма" filed Critical Общество с ограниченной ответственностью "НПК "Трифарма"
Publication of EA201301266A1 publication Critical patent/EA201301266A1/en
Publication of EA201301266A8 publication Critical patent/EA201301266A8/en
Publication of EA023024B1 publication Critical patent/EA023024B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к области медицины и химико-фармацевтической промышленности, конкретно к созданию, производству и применению лекарственного средства для лечения (купирования) болевого синдрома средней и высокой интенсивности в разных областях медицины, в частности в онкологии. Задача данного изобретения заключается в создании новых фармацевтических композиций в форме ректальных суппозиториев, содержащих налбуфин или его соль на разных суппозиторных основах, предназначенных для лечения (купирования) приступов боли от средней до высокой интенсивности, обладающих эффективным и пролонгированным анальгезирующим действием при отсутствии послабляющего эффекта, а также в разработке способов получения этих композиций. Для решения поставленной задачи предлагается применение соли налбуфина в виде суппозиторий на гидрофильной эмульсионной основе для лечения болевого синдрома умеренной и высокой интенсивности. Фармацевтическая композиция для лечения болевого синдрома умеренной и высокой интенсивности в форме суппозиториев включает в качестве действующего вещества налбуфина гидрохлорид и суппозиторную основу. В качестве суппозиторной основы композиция содержит гидрофильную эмульсионную основу, включающую формообразователи, полоксамер, наполнитель, эмульгатор, пропиленгликоль и полиэтиленоксид 400 в качестве растворителя. При этом в качестве формообразователей композиция предпочтительно содержит полиэтиленоксид 4000 и полиэтиленоксид 1500, а полоксамер представляет собой полоксамер 188. При этом в качестве наполнителя композиция предпочтительно содержит твердый жир. Кроме того, в качестве эмульгатораThe invention relates to the field of medicine and the pharmaceutical industry, specifically to the creation, production and use of a medicament for the treatment (relief) of moderate and high intensity pain in various fields of medicine, in particular in oncology. The objective of this invention is to create new pharmaceutical compositions in the form of rectal suppositories containing nalbuphine or its salt on different suppository bases, intended for the treatment (relief) of moderate to high intensity pain attacks with an effective and prolonged analgesic effect in the absence of a laxative effect, and also in the development of methods for producing these compositions. To solve this problem, the use of nalbuphine salt in the form of suppositories on a hydrophilic emulsion base for the treatment of moderate and high intensity pain syndrome is proposed. The pharmaceutical composition for the treatment of moderate to high intensity pain in the form of suppositories includes nalbuphine hydrochloride and a suppository base as the active ingredient. As a suppository base, the composition contains a hydrophilic emulsion base, including formers, poloxamer, filler, emulsifier, propylene glycol and polyethylene oxide 400 as a solvent. Moreover, the composition preferably comprises polyethylene oxide 4000 and polyethylene oxide 1500 as forming agents, and the poloxamer is poloxamer 188. Moreover, the composition preferably contains solid fat as a filler. In addition, as an emulsifier

EA201301266A 2012-11-23 2013-11-19 Pharmaceutical composition containing nalbuphine hydrochloride, use thereof to treat moderate to severe pain and method for producing said pharmaceutical composition EA023024B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012150118/15A RU2513514C1 (en) 2012-11-23 2012-11-23 Pharmaceutical composition containing nalbuphine hydrochloride, using it for treating moderate to severe pain syndrome

Publications (3)

Publication Number Publication Date
EA201301266A1 true EA201301266A1 (en) 2014-05-30
EA201301266A8 EA201301266A8 (en) 2015-07-30
EA023024B1 EA023024B1 (en) 2016-04-29

Family

ID=50480928

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301266A EA023024B1 (en) 2012-11-23 2013-11-19 Pharmaceutical composition containing nalbuphine hydrochloride, use thereof to treat moderate to severe pain and method for producing said pharmaceutical composition

Country Status (5)

Country Link
EA (1) EA023024B1 (en)
MD (1) MD4451C1 (en)
RU (1) RU2513514C1 (en)
UA (1) UA108307C2 (en)
WO (1) WO2014081343A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2562878T3 (en) 2007-05-25 2016-03-08 Indivior Uk Limited Sustained release formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
RU2646495C2 (en) * 2015-12-28 2018-03-05 Общество с ограниченной ответственностью "Научно-техническая производственная фирма "Анта-Медикал" Pharmaceutical compositions as rectal suppositories containing nefopam hydrochloride (versions), their application for treatment of acute and chronic pain syndrome and methods for production
RU2661617C1 (en) * 2017-11-23 2018-07-17 Общество с ограниченной ответственностью "Научно-техническая производственная фирма "Анта-Медикал" Nephopam suppositories for the treatment of acute and chronic pain syndrome on a hydrophilic emulsion based and method for their preparation
RU2661618C1 (en) * 2017-11-23 2018-07-17 Общество с ограниченной ответственностью "Научно-техническая производственная фирма "Анта-Медикал" Nephopam suppositories for the treatment of acute and chronic pain syndrome on a lipophilic basis and the method for their preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE102004021992A1 (en) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topical preparation containing ambroxol
RU2356535C2 (en) * 2007-07-23 2009-05-27 Закрытое Акционерное Общество "Биокад" Synergistic suppositories for infectious gynecopathies treatment (versions)
RU2363446C1 (en) * 2008-02-26 2009-08-10 Евгений Федорович Кира Suppositories for treating gynaecological and urological diseases based on dead sea dirt (versions)
RU2479305C2 (en) * 2010-12-06 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical composition for treating infectious inflammatory diseases and method for preparing it

Also Published As

Publication number Publication date
RU2513514C1 (en) 2014-04-20
WO2014081343A2 (en) 2014-05-30
MD4451B1 (en) 2016-12-31
MD20150057A2 (en) 2015-09-30
EA201301266A8 (en) 2015-07-30
UA108307C2 (en) 2015-04-10
MD4451C1 (en) 2017-07-31
WO2014081343A3 (en) 2014-08-28
EA023024B1 (en) 2016-04-29

Similar Documents

Publication Publication Date Title
EA201301266A8 (en) PHARMACEUTICAL COMPOSITION CONTAINING NALBUFIN HYDROCHLORIDE, ITS APPLICATION FOR THE TREATMENT OF MEDICAL SYNDROME OF MEDIUM AND HIGH INTENSITY AND METHOD OF OBTAINING THE PHARMACEUTICAL COMPOSITION
CY1122984T1 (en) CARBAMIDE COMPOUNDS AND METHODS OF THEIR PREPARATION AND USE
EA201800064A1 (en) 1,1,1-TRIFTOR-3-HYDROXYPROPAN-2-IL CARBAMATE DERIVATIVES AND 1,1,1-TRIFTOR-4-HYDROXYBUTAN-2-IL CARBAMATE DERIVATIVES AS MIGL INHIBITORS
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
RU2013121788A (en) HIV REPLICATION INHIBITORS
EA202092456A2 (en) COMBINATION THERAPY INCLUDING MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR TREATMENT OF VARIOUS TYPES OF CANCER
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201490647A1 (en) DERIVATIVES OF BENZOTHIAZOL-6-LUCUS ACID AND THEIR APPLICATION FOR THE TREATMENT OF HIV INFECTION
EA201492290A1 (en) COMPOSITIONS AND METHODS FOR VAGINAL DELIVERY OF ANTIPROGHESTINES
EA201491773A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKININIMODE AND DIMETYL FUMARATE
EA201691155A1 (en) COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
EA201691490A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BRINZOLAMIDE
EA201891575A1 (en) COMPOSITIONS FOR THE TREATMENT OF URINARY BUBBLE CANCER
EA201590191A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKININIMODA AND FAMPRIDINE
EA201490045A1 (en) DEUTERED 1-PIPERAZINO-3-PHENYLINDANES USED TO TREAT SCHIZOPHRENIA
EA201500710A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HIV INFECTIONS
EA201691299A1 (en) APPLICATION OF LACHINIMODA TO SLOW DOWN THE PROGRESSION OF HANTINGTON'S DISEASE
BR112015001627A2 (en) pharmaceutical composition, their uses and method of decreasing the frequency of urination
EA201591653A1 (en) COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS USING DIPYRIDAMOL
SG10201908690WA (en) Novel method of use and compositions
BR112015008155A2 (en) combinations
BR112014029838A2 (en) n - ((s) -2,3-dihydroxy-propyl) -3- (2-fluoro-4-iodo-phenylamino) -isonicotinamide solid-state forms
EA201390345A1 (en) THERAPEUTIC HOSE MEDICINE

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU